Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer Journal Article
| Authors: | D’Andrea, D.; Soria, F.; Grotenhuis, A. J.; Cha, E. K.; Malats, N.; Di Stasi, S.; Joniau, S.; Cai, T.; van Rhijn, B. W. G.; Irani, J.; Karnes, J.; Varkarakis, J.; Baniel, J.; Palou, J.; Babjuk, M.; Spahn, M.; Ardelt, P.; Colombo, R.; Serretta, V.; Dalbagni, G.; Gontero, P.; Bartoletti, R.; Larré, S.; Malmstrom, P. U.; Sylvester, R.; Shariat, S. F. |
| Article Title: | Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer |
| Abstract: | Purpose: To investigate the association of patients’ sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette–Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC). Materials and methods: We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients’ sex with HG-recurrence and disease progression. Results: A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01–1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92–1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients’ sex was not associated with recurrence (HR 0.99, 95%CI 0.80–1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78–1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78–1.60, p = 0.55). Conclusion: Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response. © 2021, The Author(s). |
| Keywords: | recurrence; bladder cancer; age; progression; response; bcg |
| Journal Title: | World Journal of Urology |
| Volume: | 39 |
| Issue: | 9 |
| ISSN: | 0724-4983 |
| Publisher: | Springer |
| Date Published: | 2021-09-01 |
| Start Page: | 3337 |
| End Page: | 3344 |
| Language: | English |
| DOI: | 10.1007/s00345-021-03653-1 |
| PROVIDER: | scopus |
| PMCID: | PMC8510956 |
| PUBMED: | 33713162 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work